Австралия - английский - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - valganciclovir hydrochloride -

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - valganciclovir hydrochloride - oral tablet - 450mg

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - valganciclovir hydrochloride - oral tablet - 450mg

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - valganciclovir hydrochloride - oral tablet - 450mg

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - valganciclovir hydrochloride - oral tablet - 450mg

Соединенные Штаты - английский - NLM (National Library of Medicine)

american health packaging - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - valganciclovir 450 mg - treatment of cytomegalovirus (cmv) retinitis: valganciclovir tablets are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)]. prevention of cmv disease: valganciclovir tablets are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1)]. prevention of cmv disease : valganciclovir tablets are indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2)]. valganciclovir is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component o

Соединенные Штаты - английский - NLM (National Library of Medicine)

dr. reddy's laboratories limited - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - valganciclovir 450 mg - treatment of cytomegalovirus (cmv) retinitis: valganciclovir tablets are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1) ]. prevention of cmv disease: valganciclovir tablets are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1) ]. prevention of cmv disease : valganciclovir tablets are indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk  [see clinical studies (14.2) ]. valganciclovir is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1) ]. risk summary after oral administration, va

Соединенные Штаты - английский - NLM (National Library of Medicine)

northstar rx llc - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - valganciclovir 450 mg - treatment of cytomegalovirus (cmv) retinitis: valganciclovir tablets are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1) ]. prevention of cmv disease: valganciclovir tablets are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1) ]. prevention of cmv disease : valganciclovir tablets are indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2) ]. valganciclovir is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1) ]. risk summary after oral administration, val

Австралия - английский - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg - tablet, film coated - excipient ingredients: crospovidone; stearic acid; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; allura red ac aluminium lake; macrogol 400 - valganciclovir cw is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir cw is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - valganciclovir hydrochloride - oral tablet - 450mg